Can isosorbide (isosorbide dinitrate or isosorbide mononitrate) be used concurrently with nitroglycerin?

Concurrent Use of Isosorbide and Nitroglycerin

Yes, isosorbide dinitrate and nitroglycerin can be used together safely and are commonly combined in clinical practice, particularly in acute heart failure and acute coronary syndromes. There is no contraindication to their concurrent use, and they are frequently administered simultaneously in acute settings.

Clinical Context for Combined Use

Acute Heart Failure Management

• Intravenous nitroglycerin is the most widely used nitrate in acute heart failure, with predominantly venodilator effects that reduce preload 1
• Isosorbide dinitrate can also be administered intravenously in acute heart failure, with similar hemodynamic benefits including reductions in pulmonary capillary wedge pressure and improvements in cardiac output 1
• Both agents are recommended for patients with systolic blood pressure >110 mmHg and may be used cautiously when SBP is 90-110 mmHg 1
• The ESC guidelines explicitly list "nitroglycerine, isosorbide mononitrate, and isosorbide dinitrate" as options for continuous infusion, indicating these agents can be selected based on clinical circumstances 1

Acute Coronary Syndromes

• In acute myocardial infarction, both nitroglycerin and isosorbide dinitrate provide antianginal effects and limit ischemic injury 2
• Isosorbide dinitrate may offer advantages over nitroglycerin in certain acute settings, with more prolonged action (up to 12 hours vs. shorter duration for nitroglycerin) and less effect on heart rate and blood pressure 2

Practical Considerations for Combined Therapy

Transition from Acute to Chronic Management

• A common clinical scenario involves starting IV nitroglycerin acutely, then transitioning to oral isosorbide dinitrate as the patient stabilizes
• When transitioning, the IV nitroglycerin can be tapered while oral isosorbide dinitrate is initiated, with brief overlap being safe and often beneficial 1

Chronic Heart Failure with Hydralazine Combination

• For chronic heart failure management, isosorbide dinitrate (not mononitrate) is the recommended nitrate formulation, particularly when combined with hydralazine 1, 3
• The target dose is 40 mg three times daily, which naturally provides a nitrate-free interval to prevent tolerance 1, 3
• This combination has Class I, Level A evidence for African American patients with NYHA class III-IV heart failure on optimal therapy 1

Important Safety Warnings

Blood Pressure Monitoring

• Slow titration and frequent blood pressure measurement is essential when using any nitrate, especially when combining formulations 1
• Avoid all nitrates when systolic blood pressure is <90 mmHg, as this may reduce central organ perfusion 1

Absolute Contraindication

• Never combine any nitrate (isosorbide or nitroglycerin) with phosphodiesterase-5 inhibitors (sildenafil, tadalafil) due to risk of profound hypotension, myocardial infarction, and death 3, 4

Tolerance Considerations

Cross-Tolerance Between Nitrates

• Chronic use of isosorbide dinitrate can attenuate the venodilator response to nitroglycerin, though arteriolar dilation remains intact 5
• This cross-tolerance primarily affects venous capacitance rather than arterial effects 5
• Maintaining a nitrate-free interval of 10-14 hours daily prevents tolerance development and preserves clinical efficacy 6, 3
• The three-times-daily dosing of isosorbide dinitrate naturally provides this interval, whereas continuous IV nitroglycerin may lead to tolerance after 24-48 hours 1, 6

Clinical Implications

• When using both agents, consider that prolonged IV nitroglycerin may reduce subsequent responsiveness to oral nitrates 5
• Combination with ACE inhibitors or hydralazine may help minimize tolerance development 6

Common Pitfalls to Avoid

• Do not substitute isosorbide mononitrate for isosorbide dinitrate in heart failure management—only dinitrate has proven mortality benefit 3
• Headache occurs in up to 82% of patients but typically improves with continued therapy; nearly 10% cannot tolerate nitrates due to disabling headaches 4
• Avoid abrupt discontinuation of chronic nitrate therapy, as nitrate rebound with nocturnal anginal episodes may occur 4